Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16711-91-4

Post Buying Request

16711-91-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16711-91-4 Usage

Description

11-Monoketofusidic acid, also known as 11-Keto Fusidic Acid, is a metabolite of Fusidic Acid. It is derived from the metabolism of Fusidic Acid, which is a steroidal antibiotic used for its antibacterial properties.

Uses

Used in Pharmaceutical Industry:
11-Monoketofusidic acid is used as an intermediate in the synthesis of Fusidic Acid for its antibacterial properties. It plays a crucial role in the development of new antibiotics and the improvement of existing ones, contributing to the fight against bacterial infections.
Used in Research and Development:
11-Monoketofusidic acid is used as a research compound for studying the metabolic pathways of Fusidic Acid and understanding its pharmacological effects. This knowledge can be applied to optimize the drug's efficacy and safety profile, as well as to develop new drugs with similar or improved properties.
Used in Quality Control:
11-Monoketofusidic acid is used as an impurity reference standard in the quality control of pharmaceutical products containing Fusidic Acid. It helps ensure the purity, potency, and safety of these products by providing a reference for the identification and quantification of related substances.
Used in Drug Metabolism Studies:
11-Monoketofusidic acid is used in drug metabolism studies to understand how Fusidic Acid is processed and eliminated from the body. This information is vital for determining the appropriate dosage, frequency, and duration of treatment, as well as for predicting potential drug interactions and side effects.

Check Digit Verification of cas no

The CAS Registry Mumber 16711-91-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,7,1 and 1 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 16711-91:
(7*1)+(6*6)+(5*7)+(4*1)+(3*1)+(2*9)+(1*1)=104
104 % 10 = 4
So 16711-91-4 is a valid CAS Registry Number.
InChI:InChI=1/C31H46O6/c1-7-26(34)37-25-16-31(6)21-12-11-20-18(4)23(32)13-14-30(20,5)28(21)24(33)15-22(31)27(25)19(29(35)36)10-8-9-17(2)3/h9,18,20-23,25,28,32H,7-8,10-16H2,1-6H3,(H,35,36)/b27-19-/t18-,20?,21-,22-,23+,25-,28-,30-,31+/m0/s1

16711-91-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 11-Ketofusidinsaeure

1.2 Other means of identification

Product number -
Other names 11-Keto Fusidic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16711-91-4 SDS

16711-91-4Downstream Products

16711-91-4Relevant articles and documents

Synthesis of Fusidic Acid Derivatives Yields a Potent Antibiotic with an Improved Resistance Profile

Garcia Chavez, Martin,Garcia, Alfredo,Lee, Hyang Yeon,Lau, Gee W.,Parker, Erica N.,Komnick, Kailey E.,Hergenrother, Paul J.

, p. 493 - 505 (2021)

Fusidic acid (FA) is a potent steroidal antibiotic that has been used in Europe for more than 60 years to treat a variety of infections caused by Gram-positive pathogens. Despite its clinical success, FA requires significantly elevated dosing (3 g on the first day, 1.2 g on subsequent days) to minimize resistance, as FA displays a high resistance frequency, and a large shift in minimum inhibitory concentration is observed for resistant bacteria. Despite efforts to improve on these aspects, all previously constructed derivatives of FA have worse antibacterial activity against Gram-positive bacteria than the parent natural product. Here, we report the creation of a novel FA analogue that has equivalent potency against clinical isolates of Staphylococcus aureus (S. aureus) and Enterococcus faecium (E. faecium) as well as an improved resistance profile in vitro when compared to FA. Importantly, this new compound displays efficacy against an FA-resistant strain of S. aureus in a soft-tissue murine infection model. This work delineates the structural features of FA necessary for potent antibiotic activity and demonstrates that the resistance profile can be improved for this scaffold and target.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16711-91-4